News FDA turns down Hetlioz for jet lag once again Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.
News Court sides with Vanda over FDA's Hetlioz rejection A court has ordered the FDA to revisit a decision to turn down a drug for jet lag developed by Vanda, potentially setting a crucial legal precedent.
News Vanda Pharmaceuticals "perplexed" by FDA rejection of jet la... The FDA has issued a dreaded Complete Response Letter to Vanda Pharmaceuticals, rejecting the company’s jet lag drug Hetlioz (tasimelteon
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
